Clinical Trials

April 19, 2014

A multi-center, double-blind, randomized, placebo-controlled, Phase 3 study to assess the efficacy and safety of oral BPS-314d-MR added-on to treprostinil inhaled (Tyvaso) in subjects with pulmonary arterial hypertension

  • Study Sponsor: Lung Biotechnology Inc. (subsidiary of United Therapeutics)
  • Start Date: 06/2013
  • End Date: 06/2016
  • Design: Placebo-controlled - Background treatment allowed
  • Age range (years): from 18 to 80
  • Type of PH
    • All PAH (Group 1 PH)
    • IPAH
    • Heritable - APAH
    • CTD - APAH
    • HIV - APAH
    • Anorexigen/Toxin - APAH
    • PAH associated with repaired congenital systemic-to-pulmonary shunts (repaired for 1 or more years)
  • Study Duration for individual patient: 1-3 years
  • Contact: Tracy Newbold (tnewbold@lungbiotechnology.com)
  • Listing on clinicaltrials.gov

 

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
Webmaster@PHAssociation.org
    Privacy Policy   Virtual Tour of Website    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2014 Pulmonary Hypertension Association. All Rights Reserved.

NORD

The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.